Literature DB >> 3698859

[Continuous intravenous or intra-arterial administration via a subcutaneous implantable infusion chamber. Preliminary clinical experiences with particular reference to intra-arterial chemotherapy].

M Lorenz, C Hottenrott, R M Seufert, M Kirkowa-Reimann, A Encke.   

Abstract

An infusion chamber was implanted subcutaneously in 18 patients for intravenous systemic treatment and in 20 for intra-arterial treatment of the liver. Intravenous catheters were introduced via the cephalic vein, intra-arterial ones via the gastroduodenal artery, after exclusion of extrahepatic metastases. Six manageable complications were observed during a total implantation time of 102 months for i.v. treatment and usage over 500 days: three temporary occlusions; one infection; two extravasations. The intra-arterial chemotherapy, largely for hepatic metastases of breast carcinoma, was undertaken according to a modified FAM schema (fluorouracil, adriamycin, mitomycin C): It achieved a high response rate with two full and eleven partial remissions. Complications were rare, except for 4 temporary occlusions. Systemic side effects were almost completely absent, local toxicity was low. One problem was the fixation of the needle which connects to the infusion chamber. This was true for both intravenous and intra-arterial treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698859     DOI: 10.1055/s-2008-1068530

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  [A totally implantable permanent central venous access, long-term experience with subcutaneous infusion chambers].

Authors:  M Lorenz; C Hottenrott; R M Seufert; A Encke
Journal:  Langenbecks Arch Chir       Date:  1988

2.  [The Huber needle as a special cannula for the puncture of implanted ports and pumps--a mistake in multiple variations].

Authors:  H Müller; J Zierski
Journal:  Klin Wochenschr       Date:  1988-10-03

Review 3.  GPCR and Alcohol-Related Behaviors in Genetically Modified Mice.

Authors:  Jérémie Neasta; Emmanuel Darcq; Jérôme Jeanblanc; Sebastien Carnicella; Sami Ben Hamida
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.